Biologics/Immunotherapy News

Two-thirds of toddlers with peanut allergy who used the VIASKIN Peanut patch from DBV Technologies completed an oral food challenge at 36 months without meeting criteria for stopping, according to a webinar held by the company.

Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 weeks of treatment, with responses as early as week 1, according to an online presentation by Jasper Therapeutics.

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.

BOSTON — Managing food allergies should involve more than just allergen avoidance, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Although this year brought many advances in the treatment of food allergy, the FDA’s approval of omalizumab dominated our most popular coverage.

This year brought breakthroughs and important advances in asthma and allergy. Healio’s most popular stories in 2024 covered the long-anticipated approval of neffy epinephrine nasal spray and an update to anaphylaxis practice parameters.

Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Dupilumab was more effective than omalizumab, benralizumab and mepolizumab in treating patients with severe asthma, according to a pair of abstracts presented at European Respiratory International Congress.